84 Recent studies highlight the pivotal role of radiotherapy in improving treatment outcomes for elderly lymphoma patients while minimising adverse effects. With an ageing population increasingly susceptible to haematological malignancies such as Hodgkin lymphoma and diffuse large B-cell lymphoma, tailored therapeutic approaches are critical. Traditional systemic therapies often present significant challenges for elderly patients due to co-morbidities, reduced functional capacity, and higher susceptibility to treatment-related complications. The findings were published in the journal Seminars in Radiation Oncology. Radiotherapy, long recognised for its effectiveness in achieving local tumour control, has evolved significantly over the decades. Advances in radiation techniques now enable precise targeting, reducing exposure to healthy tissues and minimising toxicity. These developments are particularly relevant for elderly patients, many of whom struggle to tolerate intensive chemotherapy. By allowing a reduction in chemotherapy cycles or dosages, radiotherapy helps balance treatment efficacy with quality of life considerations. In cases of early-stage follicular lymphoma, radiotherapy has demonstrated superior survival rates compared to observation alone. Evidence from the FORT trial underscores the efficacy of low-dose radiotherapy, which achieves high progression-free survival rates while maintaining minimal side effects. For diffuse large B-cell lymphoma, integrating radiotherapy into treatment regimens has been shown to improve local control and potentially prolong overall survival, particularly in patients with early-stage or bulky disease. Elderly patients also benefit from a response-adapted approach, where radiotherapy dosage and duration are tailored based on individual patient assessments and tumour response. This personalised strategy addresses frailty and co-morbidities, ensuring that treatments remain effective without overburdening the patient. Studies indicate that low-dose radiotherapy, often as minimal as 4 Gray, is effective for managing indolent lymphomas and alleviating symptoms in advanced cases. In Hodgkin lymphoma, the combination of radiotherapy with shorter chemotherapy regimens has proven effective in reducing treatment duration and chemotherapy-induced toxicity. While older patients with Hodgkin lymphoma generally experience poorer outcomes compared to younger cohorts, radiotherapy continues to play a vital role in improving progression-free survival and enhancing treatment compliance. Despite these advancements, there remains an urgent need for clinical trials focusing specifically on elderly populations. Most existing studies are under-representative of this demographic, limiting the generalisability of findings. Incorporating comprehensive geriatric assessments into treatment planning could further optimise outcomes by accounting for the unique challenges faced by older patients. Radiotherapy, when integrated into a comprehensive treatment plan, offers a viable solution for addressing the complexities of managing lymphoma in elderly patients. By enhancing local tumour control, reducing dependency on intensive systemic therapies, and mitigating treatment-related toxicities, it provides a critical pathway to better outcomes and improved quality of life.